Berberine Suppresses SASP via RXRα/PPARγ/NEDD4 in Atherosclerosis

Study Background and Research Question

Chronic inflammation driven by the accumulation of senescent cells is a key factor in the development and progression of age-related diseases, including atherosclerosis. Senescent cells, particularly macrophage-derived foam cells, actively release pro-inflammatory factors—collectively termed the senescence-associated secretory phenotype (SASP)—which exacerbate vascular inflammation and tissue remodeling. Although berberine (BBR), a plant-derived isoquinoline alkaloid, has demonstrated anti-senescent and anti-inflammatory effects, its precise mechanism in the context of atherosclerotic SASP regulation has remained unclear. The study by Zheng et al. specifically investigates: How does berberine modulate molecular pathways to suppress SASP-related inflammation in atherosclerosis (internal summary)?

Key Innovation from the Reference Study

The core innovation in Zheng et al.'s work lies in delineating the RXRα/PPARγ/NEDD4 signaling axis as the mechanistic link by which berberine exerts anti-inflammatory and anti-senescent effects in atherosclerosis. By integrating transcriptomic analysis with targeted genetic perturbation, the study provides direct evidence that berberine activates RXRα and PPARγ, leading to upregulation of the E3 ubiquitin ligase NEDD4. This, in turn, promotes ubiquitination and degradation of the GATA4/p62 complex—a critical mediator of SASP protein production—ultimately suppressing pro-inflammatory cytokine release in foam cells. Notably, the study demonstrates that interfering with RXRα disrupts this axis and negates the therapeutic benefits of berberine, establishing the essentiality of this pathway in SASP modulation (internal review).

Methods and Experimental Design Insights

To dissect the mechanistic underpinnings of berberine's anti-SASP activity, the authors employed a multifaceted approach:

• Single-cell RNA sequencing of human carotid artery plaques revealed enrichment of senescent, pro-inflammatory macrophage-derived foam cells in atherosclerotic lesions.
• Mouse models (ApoE^-/- mice) fed a high-fat diet were used to recapitulate atherosclerosis and SASP-driven inflammation in vivo. Berberine was administered to assess changes in plaque morphology, inflammatory protein expression, and blood biochemistry.
• RAW264.7 and peritoneal macrophage-derived foam cells served as in vitro models for SASP and pathway interrogation. Smart-seq analysis was used to profile transcriptomic changes upon berberine treatment.
• Lentivirus-mediated knockdown of RXRα in macrophages within atherosclerotic plaques allowed direct testing of RXRα's role in mediating berberine’s effects.

Key molecular endpoints included measurement of SASP-associated cytokines, GATA4 binding to p62, and levels of ubiquitination, alongside pathway-specific gene expression profiling.

Core Findings and Why They Matter

The study provides several pivotal findings (internal summary):

• Berberine suppresses SASP in atherosclerosis: Treatment with berberine significantly reduced the abundance of SASP-associated inflammatory proteins in both animal models and cultured foam cells.
• Activation of RXRα/PPARγ/NEDD4 axis: Smart-seq and functional assays demonstrated that berberine activates RXRα and PPARγ, which synergistically enhance NEDD4 transcription. NEDD4, in turn, promotes ubiquitination and degradation of the GATA4/p62 complex, a critical driver of SASP protein production.
• Genetic proof of mechanism: Knockdown of RXRα in macrophages abrogated the anti-inflammatory and anti-senescent effects of berberine, validating the necessity of this axis for therapeutic action.
• Implications for inflammatory aging: These findings position the RXRα/PPARγ/NEDD4 pathway not only as a mediator of berberine's effects, but also as a promising target for broader interventions in inflammatory aging and cardiovascular disease.

This mechanistic clarity is particularly important given the growing interest in SASP modulation as a therapeutic strategy for age-related diseases, and the challenges in translating anti-senescent therapies from models to clinical practice.

Comparison with Existing Internal Articles

Several recent reviews and scenario-driven guides highlight the importance of the RXRα/PPARγ/NEDD4 pathway and the potential of pharmacological antagonists and agonists in dissecting its role:

• The article "Berberine Modulates RXRα/PPARγ/NEDD4 to Suppress SASP in Atherosclerosis" (link) provides complementary evidence, reinforcing the mechanistic link between berberine, NEDD4-mediated ubiquitination, and SASP suppression in macrophage-derived foam cells.
• In contrast, "T0070907: Redefining PPARγ Antagonism for Translational Research" (link) and "Optimizing PPARγ Pathway Studies: Scenario Insights with T0070907" (link) focus on the utility of selective PPARγ antagonists, such as T0070907, in experimentally disrupting PPARγ signaling. These resources emphasize the compound’s nanomolar potency, its use in blocking adipogenesis, and its application in cell cycle studies, providing a practical toolkit for researchers seeking to precisely modulate PPARγ-dependent pathways in vitro.

Together, these internal articles bridge mechanistic insight with experimental application, underscoring the need for both pathway-specific modulators and robust workflow design in inflammation and aging research.

Limitations and Transferability

While the study offers a detailed pathway analysis and validates the requirement of the RXRα/PPARγ/NEDD4 axis in berberine-mediated SASP suppression, several limitations should be noted:

• Translational scope: The models used—mouse atherosclerosis and murine macrophage-derived foam cells—recapitulate key aspects of human disease, but interspecies differences may influence transferability to clinical settings.
• Pharmacological specificity: Berberine is a pleiotropic molecule, and while the study provides genetic validation, off-target effects cannot be fully excluded without comprehensive profiling.
• Pathway complexity: The RXRα/PPARγ/NEDD4 axis is one of several pathways involved in SASP regulation, and compensatory mechanisms may arise in different cellular contexts or disease stages.

Despite these considerations, the mechanistic focus on ubiquitin-mediated degradation of the GATA4/p62 complex provides a robust framework for further exploration and therapeutic targeting.

Protocol Parameters

• Berberine dosing in vivo: Administered to ApoE^-/- mice on a high-fat diet; specific dosing regimens should be referenced from the original study or optimized based on pilot titration.
• Foam cell generation: RAW264.7 or peritoneal macrophages exposed to oxidized LDL to induce foam cell phenotype prior to berberine or antagonist treatment.
• RXRα knockdown: Lentivirus-mediated shRNA delivery to macrophages in vitro or via targeted delivery in vivo; efficiency should be validated by qPCR or Western blot.
• Measurement endpoints: SASP-associated cytokines (IL-6, TNF-α, etc.), GATA4/p62 complex formation, and NEDD4 expression assessed by ELISA, immunoprecipitation, and qPCR.
• PPARγ pathway inhibition: For studies requiring precise inhibition of PPARγ, nanomolar antagonists such as T0070907 can be incorporated as pathway tools, with recommended working concentrations based on IC50 data and cell line sensitivity (product information).

Research Support Resources

To enable further mechanistic exploration of the PPARγ signaling pathway in SASP and atherosclerosis models, researchers may consider using selective antagonists. T0070907 (SKU A4301) is a potent and selective PPARγ antagonist with nanomolar affinity, suitable for dissecting PPARγ-dependent transcriptional events and pathway modulation in both metabolic and inflammatory contexts. When designing experiments involving PPARγ inhibition, reference concentrations and storage conditions should be consulted directly from the supplier. For additional workflow insights, see "T0070907: Precision PPARγ Antagonist for Pathway Dissection".